Jasper Therapeutics stockholders approve 2024 equity plans; amended employment agreements for CEO and other executives

Jasper Therapeutics, Inc.

Stockholders voted 10.3M for, 95K against to approve 2024 Equity Incentive Plan.
Stockholders voted 10.4M for, 12K against to approve 2024 Employee Stock Purchase Plan.
CEO Martell's annual salary remains $727,272; target bonus 50% of base; severance 18 months base plus COBRA.
CFO Cross salary $476,100; COO Mahal $481,301; CMO Tucker $514,500; each target bonus 45% of base.
Company terminated prior severance plan in favor of individual employment agreements.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.